MedTrace Logo

Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.

NCT03334552 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-11-28

No results posted yet for this study

Summary

In natural HIV disease, a small fraction (1-2%) of infected individuals develops exceptionally high titres of HIV-1 neutralizing serum activity. Antibodies isolated from these individuals have been shown to be highly active against a broad range of different HIV strains and are therefore called broadly neutralizing antibodies (bNAbs). These antibodies are in fact able to prevent (S)HIV infection in animal models and therefore of great interest for the development of an HIV vaccine. Information of neutralizing antibodies in patients from Africa is still scarce and would be of great value in the development of adapted HIV vaccine strategies in these regions. This study aims to investigate African HIV-infected individuals, who have developed neutralizing antibodies using highly specialized laboratory methodologies.

Conditions

Sponsors & Collaborators

  • National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC)

    collaborator UNKNOWN

  • University Clinic of Cologne, Department of Internal Medicine, Center for Molecular Medicine Cologne (CMMC)

    collaborator UNKNOWN

  • Max von Pettenkofer-Institute of the University of Munich (LMU), Department of Virology

    collaborator UNKNOWN

  • Michael Hoelscher

    lead OTHER

Principal Investigators

  • Arne Kroidl, Dr. · Medical Center of the University of Munich, Division of Infectious Diseases and Tropical Medicine, Germany

  • Wiston William, Dr. · NIMR-Mbeya Medical Research Center (MMRC), Tazania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2024-05-31
Completion
2024-08-31

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334552 on ClinicalTrials.gov